search
Back to results

CALM-AD

Primary Purpose

Alzheimer's Disease

Status
Unknown status
Phase
Phase 4
Locations
United Kingdom
Study Type
Interventional
Intervention
Donepezil
Sponsored by
Institute of Psychiatry, London
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Alzheimer's Disease focused on measuring Dementia

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: a diagnosis of dementia consistent with Diagnostic and Statistical Manual of Mental Health Disorders, revised 3rd edition (DSM-III-R) (APA, 1987) National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) diagnostic criteria for probably or possible AD (MKhann et al, 1984) (Appendix 6) clinically significant agitation (defined as causing distress to patient and at least moderate management problems for carers on at least two days per week for a two week period, together with a Cohen Mansfield Agitation Inventory (CMAI) (Cohen-Mansfield, 1986) (Appendix 11 A) score >39 age >39 years resident in care facility or community living with a carer not receiving treatment with neuroleptics or cholinesterase inhibitors currently or in the past four weeks and responsible clinician not considering treatment with cholinesterase inhibitor for the next 16 weeks taking into account the clinical evidence base and NICE guideline (NICE, 2001) patient with capacity willing to consent to study or will to participate in study if lacking capacity carer with capacity willing to consent to study and in agreement for patient lacking capacity to participate if patient willing to participate - Exclusion Criteria:known sensitivity to Donepezil severe, unstable or uncontrolled medical conditions apparent from history, physical examination or investigations current evidence of delirium patient meets criteria for Probably Dementia with Lewy Bodies (McKeith et al, 1996) low probability of treatment compliance -

Sites / Locations

  • Queen Elizabeth Psychiatric Hospital
  • Department of Psychiatry for the Elderly, Leicester General Hospital
  • Institute of Psychiatry, King's College, London
  • Old Age Psychiatry, Wythenshawe Hospital, Manchester
  • Institute for Ageing and Health, Newcastle General Hospital, Newcastle
  • Department of Psychiatry, Warneford Hospital, Oxford
  • MARC, Moorgreen Hospital, Southamptom
  • Department of Old Age Psychiatry, Victoria Hospital, Swindon

Outcomes

Primary Outcome Measures

Cohen Mansfield Agitation Inventory

Secondary Outcome Measures

Neuropsychiatric Inventory
Standardized Mini-Mental State Examination
Severe Impairment Battery
Clinical Global Impression of Severity/Change

Full Information

First Posted
September 1, 2005
Last Updated
December 13, 2005
Sponsor
Institute of Psychiatry, London
Collaborators
Medical Research Council, Alzheimer's Society
search

1. Study Identification

Unique Protocol Identification Number
NCT00142324
Brief Title
CALM-AD
Official Title
A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention
Study Type
Interventional

2. Study Status

Record Verification Date
September 2005
Overall Recruitment Status
Unknown status
Study Start Date
November 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2005 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Institute of Psychiatry, London
Collaborators
Medical Research Council, Alzheimer's Society

4. Oversight

5. Study Description

Brief Summary
Primary Aim To determine whether; Donepezil is significantly better than placebo in the management of agitation in Alzheimer's Disease that has not responded to, or is inappropriate for a standardised brief psychosocial treatment Secondary Aims To determine whether; Donepezil has a significant positive or negative impact upon quality of life compared with placebo whether there is a significant difference between Donepezil and placebo with respect to cognitive performance the cost effectiveness of the pharmacological treatment for agitation

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer's Disease
Keywords
Dementia

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
Double
Allocation
Randomized
Enrollment
190 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Donepezil
Primary Outcome Measure Information:
Title
Cohen Mansfield Agitation Inventory
Secondary Outcome Measure Information:
Title
Neuropsychiatric Inventory
Title
Standardized Mini-Mental State Examination
Title
Severe Impairment Battery
Title
Clinical Global Impression of Severity/Change

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: a diagnosis of dementia consistent with Diagnostic and Statistical Manual of Mental Health Disorders, revised 3rd edition (DSM-III-R) (APA, 1987) National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) diagnostic criteria for probably or possible AD (MKhann et al, 1984) (Appendix 6) clinically significant agitation (defined as causing distress to patient and at least moderate management problems for carers on at least two days per week for a two week period, together with a Cohen Mansfield Agitation Inventory (CMAI) (Cohen-Mansfield, 1986) (Appendix 11 A) score >39 age >39 years resident in care facility or community living with a carer not receiving treatment with neuroleptics or cholinesterase inhibitors currently or in the past four weeks and responsible clinician not considering treatment with cholinesterase inhibitor for the next 16 weeks taking into account the clinical evidence base and NICE guideline (NICE, 2001) patient with capacity willing to consent to study or will to participate in study if lacking capacity carer with capacity willing to consent to study and in agreement for patient lacking capacity to participate if patient willing to participate - Exclusion Criteria:known sensitivity to Donepezil severe, unstable or uncontrolled medical conditions apparent from history, physical examination or investigations current evidence of delirium patient meets criteria for Probably Dementia with Lewy Bodies (McKeith et al, 1996) low probability of treatment compliance -
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Howard
Organizational Affiliation
Institute of Psychiatry, London
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Peter Bentham
Organizational Affiliation
Queen Elizabeth Psychiatric Hospital, Birmingham
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Richard Brown
Organizational Affiliation
Institute of Psychiatry, London
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Roger Bullock
Organizational Affiliation
Kingshill Research Centre, Victoria Hospital, Swindon
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alistair Burns
Organizational Affiliation
Wythenshawe Hospital, Manchester
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Clive Holmes
Organizational Affiliation
Moorgreen Hospital, Southampton
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robin Jacoby
Organizational Affiliation
Warneford Hospital, Oxford
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
James Lindesay
Organizational Affiliation
Leicester General Hospital, Leicester
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
John O'Brien
Organizational Affiliation
Newcastle General Hospital, Newcastle
Official's Role
Principal Investigator
Facility Information:
Facility Name
Queen Elizabeth Psychiatric Hospital
City
Birmingham
ZIP/Postal Code
B15 2QZ
Country
United Kingdom
Facility Name
Department of Psychiatry for the Elderly, Leicester General Hospital
City
Leicester
ZIP/Postal Code
LE5 4PW
Country
United Kingdom
Facility Name
Institute of Psychiatry, King's College, London
City
London
ZIP/Postal Code
SE5 8AF
Country
United Kingdom
Facility Name
Old Age Psychiatry, Wythenshawe Hospital, Manchester
City
Manchester
ZIP/Postal Code
M23 9LT
Country
United Kingdom
Facility Name
Institute for Ageing and Health, Newcastle General Hospital, Newcastle
City
Newcastle upon Tyne
ZIP/Postal Code
NE4 6BE
Country
United Kingdom
Facility Name
Department of Psychiatry, Warneford Hospital, Oxford
City
Oxford
ZIP/Postal Code
OX3 7JX
Country
United Kingdom
Facility Name
MARC, Moorgreen Hospital, Southamptom
City
Southampton
ZIP/Postal Code
S030 3JB
Country
United Kingdom
Facility Name
Department of Old Age Psychiatry, Victoria Hospital, Swindon
City
Swindon
ZIP/Postal Code
SN1 4HZ
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
17914039
Citation
Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M; CALM-AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007 Oct 4;357(14):1382-92. doi: 10.1056/NEJMoa066583.
Results Reference
derived

Learn more about this trial

CALM-AD

We'll reach out to this number within 24 hrs